Pages that link to "Item:Q641145"
From MaRDI portal
The following pages link to Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145):
Displaying 19 items.
- Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials (Q512445) (← links)
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity (Q746098) (← links)
- Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling (Q1782097) (← links)
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes (Q2057378) (← links)
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials (Q2080762) (← links)
- Adaptive designs for drug combination informed by longitudinal model for the response (Q2423165) (← links)
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
- Combining Information from Cancer Registry and Medical Records Data to Improve Analyses of Adjuvant Cancer Therapies (Q3183244) (← links)
- A Bayesian Phase I/II Trial Design for Immunotherapy (Q4559685) (← links)
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (Q4967095) (← links)
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations (Q5135528) (← links)
- A Bayesian decision‐theoretic approach to incorporate preclinical information into phase I oncology trials (Q5135538) (← links)
- A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies (Q5417921) (← links)
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology (Q5866135) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics (Q6079344) (← links)
- ComPAS: a Bayesian drug combination platform trial design with adaptive shrinkage (Q6625925) (← links)
- A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling (Q6627181) (← links)
- A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death (Q6627403) (← links)
